Commercial liso-cel produced ORR 85% and CR/CRi/CRu 56% in R/R CLL/SLL, exceeding liso-cel monotherapy outcomes in TRANSCEND CLL 004 and approximating the liso-cel+ibrutinib cohort. Pre–CAR-T exposure ...
Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results